Key statistics
On Thursday, Travere Therapeutics Inc (17R:BER) closed at 17.50, -7.41% below its 52-week high of 18.90, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.80 |
---|---|
High | 17.70 |
Low | 16.80 |
Bid | 16.60 |
Offer | 18.10 |
Previous close | 16.70 |
Average volume | 153.44 |
---|---|
Shares outstanding | 85.72m |
Free float | 85.06m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -4.52 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:52 GMT.
More ▼
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock
- Travere Therapeutics Announces Proposed Public Offering of Common Stock
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics Reports Third Quarter 2024 Financial Results
- Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
- Travere Therapeutics to Report Third Quarter 2024 Financial Results
- Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
More ▼